Trial Profile

An Open-label Phase 1b Study of E7386 in Combination With Other Anticancer Drug(s) in Subjects With Solid Tumors

Status: Recruiting

Phase of Trial: Phase I/II

Latest Information Update: 20 Jun 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Eribulin (Primary) ; Lenvatinib (Primary)
Indications Colorectal cancer; Endometrial cancer; Liver cancer; Solid tumours
Focus Adverse reactions
Sponsors Eisai Inc

Most Recent Events

22 May 2025 Results presented in the PRISM BioLab Media Release.
22 May 2025 According to a PRISM BioLab media release, enrollment of 30 patients was completed of dose expansion cohort.
22 May 2025 According to a PRISM BioLab media release, results will be presented by Eisai at the American Society of Clinical Oncology (ASCO) Congress 2025, held in Chicago, USA from May 30 to June 3, 2025.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com